Mast Therapeutics, Inc.(MSTX)- NYSEMKT
  • Feb. 10, 2014, 9:36 AM
    • Mast Therapeutics (MSTX) has agreed to acquire Aires Pharmaceuticals, a privately held clinical-stage company developing therapies for pulmonary vascular disorders, in an all-stock deal.
    • Aires' lead product, AIR001, has orphan-drug status in the U.S. and Europe for pulmonary arterial hypertension.
    • Under the terms of the transaction, Aires will receive shares representing 6% of Mast's commons stock.
    • Adam Feuerstein tweets that Mast is "paying 6M shares of stock for Aires, or roughly $5M." Feuerstein also notes that Novartis had an option to acquire Aires but has apparently decided not to take it.
    • Notwithstanding, Mast's shares are +5%. (PR)
    | Feb. 10, 2014, 9:36 AM
Company Description
Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It provides products MST-188 has cytoprotective and hemorheologic properties and inhibits inflammatory processes and... More
Sector: Healthcare
Industry: Biotechnology
Country: United States